Skip to main navigation Skip to search Skip to main content

Factors in childhood associated with lung function decline to adolescence in cystic fibrosis

  • Nelufa Begum
  • , Catherine A. Byrnes
  • , Joyce Cheney
  • , Peter J. Cooper
  • , Emmanuelle Fantino
  • , Nicholas Gailer
  • , Keith Grimwood
  • , Diana GutierrezCardenas
  • , John Massie
  • , Colin F. Robertson
  • , Peter D. Sly*
  • , Harm AWM Tiddens
  • , Claire E. Wainwright
  • , Robert S. Ware
  • *Corresponding author for this work
  • University of Queensland
  • Auckland District Health Board
  • Children’s Health Queensland
  • The Children's Hospital at Westmead
  • Queensland Health
  • Royal Children's Hospital Melbourne
  • Griffith University Queensland

Research output: Contribution to journalArticleAcademicpeer-review

14 Citations (Scopus)
68 Downloads (Pure)

Abstract

Background: Despite improvements in general health and life expectancy in people with cystic fibrosis (CF), lung function decline continues unabated during adolescence and early adult life. Methods: We examined factors present at age 5-years that predicted lung function decline from childhood to adolescence in a longitudinal study of Australasian children with CF followed from 1999 to 2017. Results: Lung function trajectories were calculated for 119 children with CF from childhood (median 5.0 [25%-75%=5.0–5.1]) years) to early adolescence (median 12.5 [25%-75%=11.4–13.8] years). Lung function fell progressively, with mean (standard deviation) annual change -0.105 (0.049) for forced vital capacity (FVC) Z-score (p<0.001), -0.135 (0.048) for forced expiratory volume in 1-second (FEV1) Z-score (p<0.001), -1.277 (0.221) for FEV1/FVC% (p<0.001), and -0.136 (0.052) for forced expiratory flow between 25% and 75% of FVC Z-score (p<0.001). Factors present in childhood predicting lung function decline to adolescence, in multivariable analyses, were hospitalisation for respiratory exacerbations in the first 5-years of life (FEV1/FVC p = 0.001, FEF25–75 p = 0.01) and bronchoalveolar lavage neutrophil elastase activity (FEV1/FVC% p = 0.001, FEV1 p = 0.05, FEF25–75 p = 0.02). No examined factor predicted a decline in the FVC Z-score. Conclusions: Action in the first 5-years of life to prevent and/or treat respiratory exacerbations and counteract neutrophilic inflammation in the lower airways may reduce lung function decline in children with CF, and these should be targets of future research.

Original languageEnglish
Pages (from-to)977-983
Number of pages7
JournalJournal of Cystic Fibrosis
Volume21
Issue number6
DOIs
Publication statusPublished - Nov 2022

Bibliographical note

Acknowledgements:
The ACFBAL study was supported by the National Health and Medical Research Council (NHMRC), Australia (grants 9937868 and 351541) and the Children's Hospital Foundation (CHF), Queensland, Australia. The CF FAB study was supported by the NHMRC, Australia (Grant 1044829). NB is supported by the Cystic Fibrosis Foundation, Inc (SLY18KO), CW was supported by the CHF (RG0692016), PDS is supported by NHMRC, Australia (1102590).

Publisher Copyright: © 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Factors in childhood associated with lung function decline to adolescence in cystic fibrosis'. Together they form a unique fingerprint.

Cite this